Michail Katsoulis

Michail Katsoulis

Auto-generated profile, based on publicly available information

Michail Katsoulis

Unit for Lifelong Health and Ageing, Institute of Cardiovascular Science, University College London, London, UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in The Lancet
Verified
Journal Article
Closed access
RBRob Beelen
Rob Beelen
OROle Raaschou-Nielsen
Ole Raaschou-Nielsen
Massimo StafoggiaMassimo Stafoggia
Massimo Stafoggia
ZAZorana Jovanovic Andersen
Zorana Jovanovic Andersen
GWGudrun Weinmayr
Gudrun Weinmayr
GHGerard Hoek
Gerard Hoek

17 January 2017 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
MKM. Katsoulis
M. Katsoulis
Vassiliki BenetouVassiliki Benetou
Vassiliki Benetou
TKT. Karapetyan
T. Karapetyan
DFD. Feskanich
D. Feskanich
FGF. Grodstein
F. Grodstein
ATA. Trichopoulou
A. Trichopoulou

1 May 2014 in Epidemiology
Verified
Journal Article
Closed access
RBRob Beelen
Rob Beelen
MSMassimo Stafoggia
Massimo Stafoggia
OROle Raaschou-Nielsen
Ole Raaschou-Nielsen
ZAZorana Jovanovic Andersen
Zorana Jovanovic Andersen
WXWei W. Xun
Wei W. Xun
GHGerard Hoek
Gerard Hoek
Air pollution has been associated with cardiovascular mortality, but it remains unclear as to whether specific pollutants are related to specific cardiovascular causes of death. Within the multicenter European Study of Cohorts for Air Pollution Effects (ESCAPE), we investigated the associations of long-term exposure to several air pollutants with all cardiovascular disease (CVD) mortality, as well as with specific cardiovascular causes of death. Data from 22 European cohort studies were used. Using a standardized protocol, study area-specific air pollution exposure at the residential address was characterized as annual average concentrations of the following: nitrogen oxides (NO2 and NOx); particles with diameters of less than 2.5 μm (PM2.5), less than 10 μm (PM10), and 10 μm to 2.5 μm (PMcoarse); PM2.5 absorbance estimated by land-use regression models; and traffic indicators. We applied cohort-specific Cox proportional hazards models using a standardized protocol. Random-effects meta-analysis was used to obtain pooled effect estimates. The total study population consisted of 367,383 participants, with 9994 deaths from CVD (including 4,992 from ischemic heart disease, 2264 from myocardial infarction, and 2484 from cerebrovascular disease). All hazard ratios were approximately 1.0, except for particle mass and cerebrovascular disease mortality; for PM2.5, the hazard ratio was 1.21 (95% confidence interval = 0.87-1.69) per 5 μg/m and for PM10, 1.22 (0.91-1.63) per 10 μg/m. In a joint analysis of data from 22 European cohorts, most hazard ratios for the association of air pollutants with mortality from overall CVD and with specific CVDs were approximately 1.0, with the exception of particulate mass and cerebrovascular disease mortality for which there was suggestive evidence for an association.

14 August 2017 in European Heart Journal
Verified
Journal Article
Open access
PDF file
CLCamille Lassale
Camille Lassale
ITIoanna Tzoulaki
Ioanna Tzoulaki
KMKarel G M Moons
Karel G M Moons
MSMichael Sweeting
Michael Sweeting
JBJolanda Boer
Jolanda Boer
ABAdam S Butterworth
Adam S Butterworth
The hypothesis of ‘metabolically healthy obesity’ implies that, in the absence of metabolic dysfunction, individuals with excess adiposity are not at greater cardiovascular risk. We tested this hypothesis in a large pan-European prospective study. We conducted a case-cohort analysis in the 520 000-person European Prospective Investigation into Cancer and Nutrition study (‘EPIC-CVD’). During a median follow-up of 12.2 years, we recorded 7637 incident coronary heart disease (CHD) cases. Using cut-offs recommended by guidelines, we defined obesity and overweight using body mass index (BMI), and metabolic dysfunction (‘unhealthy’) as ≥ 3 of elevated blood pressure, hypertriglyceridaemia, low HDL-cholesterol, hyperglycaemia, and elevated waist circumference. We calculated hazard ratios (HRs) and 95% confidence intervals (95% CI) within each country using Prentice-weighted Cox proportional hazard regressions, accounting for age, sex, centre, education, smoking, diet, and physical activity. Compared with metabolically healthy normal weight people (reference), HRs were 2.15 (95% CI: 1.79; 2.57) for unhealthy normal weight, 2.33 (1.97; 2.76) for unhealthy overweight, and 2.54 (2.21; 2.92) for unhealthy obese people. Compared with the reference group, HRs were 1.26 (1.14; 1.40) and 1.28 (1.03; 1.58) for metabolically healthy overweight and obese people, respectively. These results were robust to various sensitivity analyses. Irrespective of BMI, metabolically unhealthy individuals had higher CHD risk than their healthy counterparts. Conversely, irrespective of metabolic health, overweight and obese people had higher CHD risk than lean people. These findings challenge the concept of ‘metabolically healthy obesity’, encouraging population-wide strategies to tackle obesity.

1 February 2016 in Environment International
Verified
Journal Article
Closed access
OROle Raaschou-Nielsen
Ole Raaschou-Nielsen
RBR. Beelen
R. Beelen
MWM. Wang
M. Wang
GHG. Hoek
G. Hoek
ZAZ.J. Andersen
Z.J. Andersen
PVP. Vineis
P. Vineis

8 April 2020 in European Heart Journal
Verified
Journal Article
Open access
PSPaul R Scully
Paul R Scully
KPKush P Patel
Kush P Patel
TTThomas A Treibel
Thomas A Treibel
GTGeorge D Thornton
George D Thornton
RHRebecca K Hughes
Rebecca K Hughes
JMJames C Moon
James C Moon
Aims: Cardiac amyloidosis is common in elderly patients with aortic stenosis (AS) referred for transcatheter aortic valve implantation (TAVI). We hypothesized that patients with dual aortic stenosis and cardiac amyloid pathology (AS-amyloid) would have different baseline characteristics, periprocedural and mortality outcomes. Methods and results: Patients aged ≥75 with severe AS referred for TAVI at two sites underwent blinded bone scintigraphy prior to intervention (Perugini Grade 0 negative, 1–3 increasingly positive). Baseline assessment included echocardiography, electrocardiogram (ECG), blood tests, 6-min walk test, and health questionnaire, with periprocedural complications and mortality follow-up. Two hundred patients were recruited (aged 85 ± 5 years, 50% male). AS-amyloid was found in 26 (13%): 8 Grade 1, 18 Grade 2. AS-amyloid patients were older (88 ± 5 vs. 85 ± 5 years, P = 0.001), with reduced quality of life (EQ-5D-5L 50 vs. 65, P = 0.04). Left ventricular wall thickness was higher (14 mm vs. 13 mm, P = 0.02), ECG voltages lower (Sokolow–Lyon 1.9 ± 0.7 vs. 2.5 ± 0.9 mV, P = 0.03) with lower voltage/mass ratio (0.017 vs. 0.025 mV/g/m2, P = 0.03). High-sensitivity troponin T and N-terminal pro-brain natriuretic peptide were higher (41 vs. 21 ng/L, P < 0.001; 3702 vs. 1254 ng/L, P = 0.001). Gender, comorbidities, 6-min walk distance, AS severity, prevalence of disproportionate hypertrophy, and post-TAVI complication rates (38% vs. 35%, P = 0.82) were the same. At a median follow-up of 19 (10–27) months, there was no mortality difference (P = 0.71). Transcatheter aortic valve implantation significantly improved outcome in the overall population (P < 0.001) and in those with AS-amyloid (P = 0.03). Conclusions: AS-amyloid is common and differs from lone AS. Transcatheter aortic valve implantation significantly improved outcome in AS-amyloid, while periprocedural complications and mortality were similar to lone AS, suggesting that TAVI should not be denied to patients with AS-amyloid.